| J1-1709 |
Structural insight into the mechanism of Clostridium difficile surface formation |
1.7.2019 - 30.6.2023 |
IJS dr. Dušan Turk
FFA dr. Janez Mravljak |
|
J1-1715
|
Protein interaction atlas for prediction of genetic variations involved in drug interactions and disease development
|
1.7.2019 - 30.6.2022
|
Dušanka Janežič
|
J1-1717
|
Development of novel Hsp90 inhibitors with anticancer activity |
1.7.2019 - 30.6.2023 |
Tihomir Tomašič
|
| J1-2483 |
Radiopharmaceuticals with antagonistic activity on CCK2R
|
1.9.2020 - 31.8.2023 |
Marko Anderluh |
| J1-2484 |
Development of antibacterial compounds targeting validated enzymes in peptidoglycan biosynthesis |
1.9.2020 - 31.8.2023 |
Stanislav Gobec |
J1-2485 |
The kiss of death for key apoptosis players: development of BCL-2 and BAX PROTACs
|
1.9.2020 - 31.8.2023 |
Izidor Sosič |
|
J1-7302
|
Nanotheranostics based on magneto-responsive materials
|
1.1.2016 - 31.12.2018
|
Petra Kocbek
|
|
J1-7479
|
Structural insight into iodine metabolism
|
1.1.2016 - 31.12.2018
|
CIPKEBIP Dušan Turk
FFA Stanislav Gobec
|
|
J1-7515
|
Receptors for toxins of plant pathogens
|
1.1.2016 - 31.12.2018
|
KI Gregor Anderluh
FFA Stanislav Gobec
|
|
J1-8140
|
Endocrine disrupting and genotoxic potential of protein kinase inhibitors: relevance for environmental hazard in zdravje ljudi
|
1.5.2017 - 30.4.2020
|
NIB Metka Filipič
FFA Marija Sollner Dolenc
|
|
J1-8145
|
Dynamic aspect of ligand-protein binding
|
1.5.2017 - 30.4.2020
|
KI Simona Golič Grdadolnik
FFA Stanislav Gobec
|
|
J1-8152
|
Inhibition of Staphylococcus aureus cell wall remodeling
|
1.5.2017 - 30.4.2020
|
IJS Dušan Turk
FFA Marko Anderluh
|
|
J1-9192
|
New anticancer leads for emerging cancer target potassium ion channels hEag1 and its validation in lymphoma tumors
|
1.7.2018 - 30.6.2021
|
Lucija Peterlin Mašič
|
|
J1-9194
|
Nanomedicines with antibiotics and probiotics for local treatment of periodontal disease
|
1.7.2018 - 30.6.2022
|
Julijana Kristl
|
| J3-1745 |
Elucidating the role of immunoproteasome in platelet-driven immune response |
1.7.2019 - 30.6.2023 |
Martina Gobec |
| J3-1749 |
Mesenchymal stem cells-the keepers of tissue endogenous regenerative capacity facing up to aging of the musculoskeletal system |
1.7.2019 - 30.6.2023 |
Janja Zupan |
|
J3-1759
|
Comprehensive characterization of GWAS hits – pipeline to novel drug targets for anabolic treatment of osteoporosis (GWASforAna)
|
1.7.2019 - 30.6.2022
|
Janja Marc
|
J3-2517
|
Development of innate immune receptor-targeting chimeras as custom-tailored vaccine adjuvants |
1.9.2020 - 31.8.2023 |
Žiga Jakopin |
| J3-2518 |
Role of APOBEC proteins in the oncogenesis of HPV viruses |
1.9.2020 - 31.8.2023 |
UNG Martina Bergant Marušič
UL FFA Marija Nika Lovšin |
| J3-2521 |
Inflammatory process in interstitial cystitis and evaluation of the influence of cannabinoid receptor agonists in urinary bladder - from cells to patients |
1.9.2020 - 31.8.2023 |
UL MF Peter Veranič
FFA Mojca Kerec Kos |
|
J3-7245
|
Identification of new expression regulators of RANKL, a key molecule not only in bone remodelling
|
1.1.2016 - 31.12.2018
|
Janja Marc
|
|
J3-7494
|
Tunneling nanotubes for innovative urinary bladder cancer treatments
|
1.1.2016 - 31.12.2018
|
MF Mateja Erdani Kreft
Petra Kocbek
|
|
J3-8207
|
New frontiers in folate supplementation in obstetrics and gynaecology (NFFS OB-GYN)
|
1.5.2017 - 30.4.2020
|
UKC LJ Ksenija Geršak
FFA Irena Mlinarič-Raščan
|
|
J3-8210
|
Potential of low, sub-therapeutic doses of statins and sartans in primary and secondary cardiovascular disease prevention
|
1.5.2017 - 30.4.2020
|
UKC LJ Mirza Šabovič
FFA Janja Marc
|
|
J3-9256
|
Development of NOD2 agonists and dual NOD2/TLR7 agonistic conjugates as novel vaccine adjuvants
|
1.7.2018 - 30.6.2022
|
Žiga Jakopin
|
|
J3-9267
|
Inhibition of cathepsin X activity as a novel strategy for the treatment of Parkinson's disease
|
1.7.2018 - 30.6.2021
|
Anja Pišlar
|
|
J4-1767
|
Selective extraction of high value molecules from forest products processing residues in the speciality chemicals sector
|
1.7.2019 - 30.6.2022
|
InnoRenew Andreja Kutnar
FFA Samo Kreft
|
|
J4-1776
|
Improvement of immunotherapeutic potential of NK cells through modulation of cystatin F
|
1.7.2019 - 30.6.2022
|
Janko Kos
|
|
J4-1778
|
Exploitation of a virus-borne small protein to combat antibiotic resistance in Staphylococcus aureus
|
1.7.2019 - 31.12.2022
|
UL BF Matej Butala
FFA Stanislav Gobec
|
|
J4-7640
|
Electrostatic immobilisation of bacterial cells and effects on their physiology
|
1.3.2016 - 28.2.2019
|
IMMT Aleš Lapanje
FFA Julijana Kristl
|
|
J4-8227
|
Cathepsin X inhibitors impair the resistence of tumor cells to antiprotease therapy
|
1.5.2017 - 30.4.2020
|
Janko Kos
|
|
J4-9327
|
Targeting, imaging and treating of colorectal cancer with safe theranostic bacteria
|
1.7.2018 - 30.6.2021
|
JS Aleš Berlec
FFA Janko Kos
|
| J7-2603 |
Efficacy of bacteriophages for treatment of extracellular and intracelular bacterial infections of implantants |
1.9.2020 - 31.8.2023 |
UL FKKT Aleš Podgornik
UL FFA Janja Zupan |
|
L1-8157
|
Development of multifunctional compounds for treatment of Alzheimer's disease
|
1.5.2017 - 30.4.2020
|
Stanislav Gobec
|
|
L2-7550
|
Elecrospun nanofibrous materials for solid state drug delivery system
|
1.3.2016 - 28.2.2019
|
OI Igor Emri
FFA Albin Kristl
|
|
N1-0068
|
Identification of non-peptidic inhibitors of the immunoproteasome using fragment based drug discovery methods
|
1.11.2017 - 31.10.2020
|
Stanislav Gobec
|
|
N1-0098
|
Discovery and mechanism of action of novel hEag1 potassium channel lead molecules with anti-cancer activity
|
1.1.2019 - 31.12.2022
|
Lucija Peterlin Mašič
|
|
NC-0004
|
NOBIL - Novel Biomarkers in Leukemia
|
1.5.2018 - 30.4.2020
|
Irena Mlinarič Raščan
|
|
NC-0009
|
Development of new carbamate-based imaging probes for cholinesterases
|
1.4.2019 - 31.3.2021
|
Stanislav Gobec
|
|
V1-1914
|
Selection and preparation of a dossier potentially neurotoxic chemical using in silico methods for the purpose of implementing the European chemical legislation REACH
|
1.11.2019 - 31.10.2020
|
KI Marjan Vračko - Grobelšek
FFA Marija Sollner Dolenc
|
|
V3-1636
|
New psychoactive substances monitoring system in Slovenia (acronym SONDA)
|
1.10.2016 - 30.9.2018
|
UKC LJ Miran Brvar
FFA Lucija Peterlin Mašič
|
|
V4-1605
|
The use of hop products for organic control of varroa (Varroa destructor)
|
1.10.2016 - 30.9.2019
|
IHPS Košir Iztok Jože
FFA Stanko Srčič
|
|
V4-2038
|
DNA vaccine and peptide inhibitors against SARS-CoV-2
|
1.10.2020 - 30.9.2022
|
KI Roman Jerala
FFA Borut Štrukelj
|
|
Z1-1859
|
Targeted covalent inhibitors: inhibiting monoamine oxidase through non-catalytic amino-acid residues
|
1.7.2019 - 30.6.2021
|
Damijan Knez
|
|
Z1-2635
|
Modular asymmetric total synthesis of bioactive multi-chiral natural products
|
1.9.2020 - 31.8.2022
|
Andrej Emanuel Cotman
|
|
Z1-7181
|
Optimization of nitroxoline-based inhibitors of cathepsin B as potential drugs for the treatment of cancer
|
1.1.2016 - 31.12.2017
|
Izidor Sosič
|
|
Z1-8158
|
Discovery of new inhibitors of bacterial peptidoglycan biosynthesis enzymes MurA and MurB
|
1.5.2017 - 30.4.2019
|
Marko Jukič
|
|
Z1-9195
|
Butyrylcholinesterase inhibitors for alleviating symptoms of Alzheimer's disease
|
1.7.2018 - 30.6.2020
|
Urban Košak
|